HCA Healthcare
HCA
$382.19
+1.51%
HCA Healthcare is the largest operator of acute-care hospitals in the United States, owning and managing 190 hospitals and over 2,500 outpatient facilities across 19 states and the UK. As a dominant player in the Medical - Care Facilities industry, HCA benefits from scale, geographic diversification, and a strong brand in healthcare delivery. The current investor narrative centers on the company's ability to sustain growth amid an aging population and rising healthcare demand, while navigating regulatory headwinds and payer mix shifts that have recently pressured margins and revenue growth.…
HCA
HCA Healthcare
$382.19
Related headlines
HCA 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HCA Healthcare's 12-month outlook, with a consensus price target around $469.10 and implied upside of +22.7% versus the current price.
Average Target
$469.10
0 analysts
Implied Upside
+22.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$369 - $635
Analyst target range
HCA is covered by 20 analysts, with a consensus recommendation of 'Buy' (mean score 1.96 on a 5-point scale where 1 is Strong Buy). The average target price is $470.55, implying approximately +26.8% upside from the current price of $371.18. The distribution shows 10 recent ratings with a mix of Overweight, Buy, and Equal Weight, but no outright Sell ratings. This bullish consensus suggests analysts see the current weakness as temporary and expect a recovery.
The target price range spans from $370.00 (low) to $635.00 (high), a wide spread of $265, indicating high uncertainty about the stock's future. The low target of $370 is essentially at the current price, implying downside risk if fundamentals deteriorate further. The high target of $635 assumes a significant rebound, likely driven by margin recovery, volume growth, and multiple expansion. Recent rating actions show a slight negative tilt: Barclays downgraded from Overweight to Equal Weight on July 8, while Wells Fargo maintained Equal Weight. However, most firms have kept positive ratings, suggesting that the selloff may be overdone in their view. The wide target range and mixed recent actions underscore the stock's high uncertainty and the need for a catalyst to break the current downtrend.
Bulls vs Bears: HCA Investment Factors
HCA presents a classic value trap debate: deep valuation discounts (forward PE 11.3x, PEG 0.57) and strong cash flows ($7.93B FCF) argue for a buy, but decelerating revenue growth (4.3% YoY), a gross margin collapse to 15.0%, and negative equity (-8.33 D/E) signal fundamental deterioration. The bull case hinges on margin recovery and multiple expansion, while the bear case warns of further earnings erosion. The single most important tension is whether the gross margin collapse is temporary (mix shift) or structural (cost inflation/pricing pressure). Resolution of this margin question will determine if HCA is a deep-value opportunity or a falling knife.
Bullish
- Analyst consensus Buy with 26.8% upside: 20 analysts rate HCA a Buy with an average target of $470.55, implying 26.8% upside from $371.18. The low target of $370 is essentially at the current price, limiting downside risk from here.
- Forward PE of 11.3x is deeply discounted: HCA trades at 11.3x forward earnings versus the S&P 500's ~20x, a 44% discount. The PEG ratio of 0.57 suggests the stock is undervalued relative to its expected earnings growth.
- Strong free cash flow generation: TTM free cash flow is $7.93 billion, providing ample capacity for debt reduction and shareholder returns. In Q1 2026, HCA returned $1.57 billion via buybacks, demonstrating commitment to capital returns.
- Dominant market position in aging U.S. population: HCA operates 190 hospitals and 2,500 outpatient facilities, the largest acute-care network in the U.S. The aging population drives structural demand for healthcare services, supporting long-term revenue growth.
Bearish
- Revenue growth decelerating to 4.3% YoY: Q1 2026 revenue grew only 4.3% YoY, down from 6.4% in Q4 2025 and 7.0% in Q3 2025. The deceleration is driven by unfavorable payer mix, with higher exposure to lower-reimbursement government programs.
- Gross margin collapsed to 15.0% in Q1 2026: Gross margin fell from 41.9% in Q4 2025 to 15.0% in Q1 2026, a dramatic decline likely due to a shift in revenue mix or cost structure. This raises concerns about earnings quality and sustainability.
- Negative equity and high leverage: Debt-to-equity is -8.33 due to negative equity from aggressive share buybacks. The current ratio of 0.83 indicates tight liquidity, leaving little buffer for operational shocks.
- Stock in sustained downtrend, down 33% from 52-week high: HCA is down 33% from its 52-week high of $556.52 and has lost 20.9% year-to-date. The 3-month relative strength of -28.6% versus the S&P 500 shows persistent underperformance.
HCA Technical Analysis
HCA's 1-year price change of +2.37% masks a significant intra-year decline, with the stock currently trading at $371.18, just 12% above its 52-week low of $330.00 and 33% below its 52-week high of $556.52. This positioning near the low end of the range suggests a deeply oversold condition, but also reflects persistent selling pressure and a lack of bullish conviction. The stock has lost over 20% year-to-date, indicating a sustained downtrend rather than a mere pullback.
Short-term momentum is decisively bearish: the 1-month change is -4.37% and the 3-month change is -23.94%, both sharply underperforming the S&P 500's gains of +0.31% and +4.67% over the same periods. The relative strength metrics confirm this divergence, with 1-month relative strength at -4.68% and 3-month at -28.61%. This accelerating decline suggests that selling pressure is intensifying, and there is no sign of a near-term reversal. The stock's beta of 1.128 indicates slightly above-market volatility, but the current drawdown is more severe than typical market moves.
Key support lies at the 52-week low of $330.00; a break below that level would signal a new leg down and likely trigger further selling. Resistance is at the 52-week high of $556.52, but a more immediate ceiling is the $400 area, where the stock stalled in early July. The short ratio of 3.07 days suggests moderate short interest, but not extreme enough to force a squeeze. With the stock trading near its lows and momentum negative, the path of least resistance remains lower until a clear catalyst emerges.
Beta
1.13
1.13x market volatility
Max Drawdown
-33.7%
Largest decline past year
52-Week Range
$330-$557
Price range past year
Annual Return
+11.9%
Cumulative gain past year
| Period | HCA Return | S&P 500 |
|---|---|---|
| 1m | -1.4% | +0.8% |
| 3m | -11.6% | +3.5% |
| 6m | -18.8% | +7.2% |
| 1y | +11.9% | +16.5% |
| ytd | -18.8% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HCA Fundamental Analysis
HCA's revenue trajectory shows steady but decelerating growth. In Q1 2026, revenue reached $19.11 billion, up 4.3% year-over-year, compared to 6.4% growth in Q4 2025 and 7.0% in Q3 2025. The deceleration is partly due to an unfavorable payer mix, with higher exposure to government programs like Medicare ($3.06B) and Medicaid ($1.44B) versus commercial managed care ($9.08B). While the top line remains resilient, the growth rate is slowing, which could pressure the investment case if it continues to trend lower.
Profitability remains solid but margins are compressing. Net income in Q1 2026 was $1.62 billion, with a net margin of 8.5%, down from 9.6% in Q4 2025 and 8.9% in Q2 2025. Gross margin fell sharply to 15.0% in Q1 2026 from 41.9% in Q4 2025, reflecting a significant shift in cost structure or revenue mix (likely due to higher cost of revenue). Operating margin also declined to 15.0% from 16.3% in Q4 2025. Despite this, HCA remains profitable with a trailing PE of 16.3x, and the net income of $1.62B provides a solid earnings base.
HCA's balance sheet shows high leverage but strong cash generation. Debt-to-equity is -8.33 (negative equity due to share buybacks), and the current ratio of 0.83 indicates tight liquidity. However, free cash flow TTM is $7.93 billion, and operating cash flow in Q1 2026 was $2.01 billion, covering capital expenditures of $1.12 billion. The company returned $1.57 billion to shareholders via buybacks in Q1, demonstrating a commitment to shareholder returns despite leverage. ROE is negative (-112.6%) due to negative equity, but ROA of 12.3% is healthy, indicating efficient asset use.
Quarterly Revenue
$19.1B
2026-03
Revenue YoY Growth
+4.3%
YoY Comparison
Gross Margin
15.0%
Latest Quarter
Free Cash Flow
$7.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HCA Overvalued?
Since HCA has positive net income, the primary valuation metric is the PE ratio. The trailing PE is 16.3x, while the forward PE is 11.3x, implying the market expects significant earnings growth in the next year. The gap between trailing and forward PE suggests that analysts anticipate a sharp earnings recovery, which is consistent with the estimated EPS of $48.73 for the current fiscal year. The PEG ratio of 0.57 further supports a growth-at-a-reasonable-price narrative.
Compared to the industry average (Medical - Care Facilities), HCA's trailing PE of 16.3x appears reasonable. While specific industry averages are not provided, the forward PE of 11.3x is below the S&P 500's forward PE of ~20x, suggesting a discount. The EV/EBITDA of 10.1x is also moderate for a healthcare services company. Given HCA's market leadership and scale, the current valuation does not appear stretched, but the discount may reflect regulatory and payer mix risks.
Historically, HCA's trailing PE has ranged from 8.0x (Q4 2022) to 20.6x (Q3 2024). At 16.3x, the stock is in the middle of its historical range, not at extreme levels. The price-to-sales ratio of 1.42x is near the lower end of its 5-year range (which has been as high as 6.0x), indicating that the market is pricing in pessimism. This could represent a value opportunity if fundamentals stabilize, but it also reflects the current earnings headwinds.
PE
16.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 8x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HCA's balance sheet is stretched, with a debt-to-equity ratio of -8.33 (negative equity) and a current ratio of 0.83, indicating limited liquidity. The gross margin collapse from 41.9% in Q4 2025 to 15.0% in Q1 2026 is alarming, though it may partly reflect a seasonal shift in payer mix. Net margin also compressed to 8.5% from 9.6% in Q4 2025. With $1.57 billion in quarterly buybacks, the company is prioritizing shareholder returns over deleveraging, which increases financial risk if earnings deteriorate further.
Market & Competitive Risks: HCA trades at a forward PE of 11.3x, a discount to the S&P 500, but this may be warranted given the regulatory overhang and payer mix headwinds. The stock's beta of 1.128 indicates slightly above-market volatility, and the 3-month relative strength of -28.6% shows severe underperformance. Recent news highlights industry-wide admissions mix issues (Tenet Healthcare's soft Q1 sales) and regulatory uncertainty. The wide analyst target range ($370-$635) reflects high uncertainty, and the recent Barclays downgrade to Equal Weight adds to the cautious sentiment.
Worst-Case Scenario: If the gross margin collapse proves structural (e.g., due to rising labor costs or unfavorable payer mix), earnings could fall sharply, triggering multiple compression. The 52-week low of $330.00 is a key support; a break below that could lead to a decline toward the analyst low target of $370 (already near current price) or lower. In a severe recession scenario, HCA could revisit its historical PE trough of 8.0x, implying a price of ~$260 (based on estimated EPS of $32.5). From the current price of $371.18, this represents a potential loss of -30% to -40%.